Contact Us
Drug Search Results
More Filters [+]

Paclitaxel poliglumex

Alternative Names: paclitaxel poliglumex
Latest Update: 2022-12-10
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Tubulin Binder

Novel Mechanism: Yes

Modality: Large Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Uruguay

Approved Indications: None

Known Adverse Events: None

Company: CTI BioPharma
Company Location: SEATTLE WA 98121
Company CEO: Adam R. Craig
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Paclitaxel poliglumex

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer

Phase 2: Fallopian Tube Cancer|Prostate Cancer|Ovarian Cancer|Peritoneal Cancer|Non-Small-Cell Lung Cancer|Head and Neck Cancer|Esophageal Cancer|Squamous Cell Carcinoma

Phase 1: Colorectal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
X90003

P2

Completed

Head and Neck Cancer|Squamous Cell Carcinoma

2016-12-01

CTI#X64001

P2

Completed

Esophageal Cancer

2010-02-01

2007-004167-22

P3

Active, not recruiting

Non-Small-Cell Lung Cancer

2009-11-23

D-0433

P2

Completed

Non-Small-Cell Lung Cancer

2009-11-01

Recent News Events

Date

Type

Title

12/10/2022

PubMed

 Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study.

01/01/2021

PubMed

 Comparison of Efficacy and Peripheral Neuropathy of Solvent-based Paclitaxel with Paclitaxel Poliglumex and NK105: A Systematic Review and Metaanalysis.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions